Fairtree Asset Management Pty Ltd Has $2.35 Million Stock Holdings in Zoetis Inc. $ZTS

Fairtree Asset Management Pty Ltd boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 252.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,071 shares of the company’s stock after purchasing an additional 11,509 shares during the quarter. Zoetis comprises approximately 1.5% of Fairtree Asset Management Pty Ltd’s holdings, making the stock its 15th largest position. Fairtree Asset Management Pty Ltd’s holdings in Zoetis were worth $2,352,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its position in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares during the period. Empowered Funds LLC grew its position in Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after purchasing an additional 657 shares during the last quarter. Intech Investment Management LLC increased its holdings in shares of Zoetis by 17.2% during the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares during the period. Sivia Capital Partners LLC raised its position in shares of Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after buying an additional 1,422 shares during the last quarter. Finally, Assetmark Inc. lifted its stake in shares of Zoetis by 12.2% in the second quarter. Assetmark Inc. now owns 26,409 shares of the company’s stock valued at $4,119,000 after buying an additional 2,876 shares during the period. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a research note on Monday, December 15th. KeyCorp assumed coverage on Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating on the stock. BTIG Research reaffirmed a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research report on Thursday. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, January 28th. Finally, Piper Sandler restated a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $152.91.

Zoetis Stock Performance

Zoetis stock opened at $131.06 on Monday. The firm has a market capitalization of $55.32 billion, a P/E ratio of 21.77, a P/E/G ratio of 2.00 and a beta of 0.95. The stock has a fifty day moving average price of $126.05 and a two-hundred day moving average price of $133.92. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.00. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.6%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.